Provided by Tiger Trade Technology Pte. Ltd.

Tyra Biosciences, Inc.

25.30
+0.27001.08%
Post-market: 25.300.00000.00%19:58 EDT
Volume:423.51K
Turnover:10.73M
Market Cap:1.50B
PE:-10.53
High:25.59
Open:24.99
Low:24.84
Close:25.03
52wk High:40.65
52wk Low:11.70
Shares:59.49M
Float Shares:35.21M
Volume Ratio:1.41
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4031
EPS(LYR):-2.0125
ROE:-45.31%
ROA:-28.46%
PB:4.26
PE(LYR):-12.57

Loading ...

BRIEF-Tyra Biosciences Agreed To Issue 4 Million Shares At $31.50 Per Share To A Large Investment Management Firm - SEC Filing

Reuters
·
Mar 05

Tyra Biosciences- Agreed to Issue 4 Mln Shares at $31.50 per Share to a Large Investment Management Firm - SEC Filing

THOMSON REUTERS
·
Mar 05

Tyra Biosciences Inc - Expects $126.0 Mln in Gross Proceeds From Share Sale - SEC Filing

THOMSON REUTERS
·
Mar 05

Tyra Bioscience (TYRA) Gets a Buy from Piper Sandler

TIPRANKS
·
Mar 03

Tyra Biosciences: FGFR3-Focused Pipeline and Upcoming Clinical Catalysts Support Buy Rating and Favorable Risk‑Reward

TIPRANKS
·
Mar 03

Analysts’ Top Healthcare Picks: Stryker (SYK), Tyra Bioscience (TYRA)

TIPRANKS
·
Mar 03

Tyra Biosciences reports Q4 EPS (57c), consensus (53c)

TIPRANKS
·
Mar 03

Tyra Biosciences Q4 EPS $(0.57) Misses $(0.55) Estimate

Benzinga Earnings
·
Mar 03

Tyra Biosciences Q4 net loss widens on higher R&D costs

Reuters
·
Mar 03

Tyra Q4 net loss hits USD 33.8 million, up 32.3%

Reuters
·
Mar 03

Press Release: Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Dow Jones
·
Mar 03

Tyra Biosciences Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Feb 24

Cantor Fitzgerald Initiates Tyra Bioscience at Overweight

MT Newswires Live
·
Feb 24

Raymond James Reaffirms Their Buy Rating on Tyra Bioscience (TYRA)

TIPRANKS
·
Feb 24

Tyra Biosciences to Present Two Posters at 2026 ASCO GU Cancers Symposium

Reuters
·
Feb 24

Tyra Biosciences Announces Phase 2 SURF302 Study of Dabogratinib in FGFR3-Altered Non-Muscle Invasive Bladder Cancer

Reuters
·
Feb 24

Tyra Biosciences to Present at Oppenheimer Life Sciences Healthcare Conference

Reuters
·
Feb 20

Tyra Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Feb 17

Tyra Biosciences Inc : H.c. Wainwright Raises Target Price to $45 From $30

THOMSON REUTERS
·
Feb 17

Tyra Biosciences price target raised to $45 from $30 at H.C. Wainwright

TIPRANKS
·
Feb 17